1-3 of 3
Maeve Waldron-Lynch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Clinical Trials & Observations
David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (16): 1348–1358.
https://doi.org/10.1182/blood.2023020637
Published: 2023
Includes: Supplemental data
Journal Articles

First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Johannes Duell, Katerina Kopeckova, Marek Trneny, Christiane Pott, Mouhamad Khouja, John M. Burke, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Derek Blair, David Belada
Journal: Blood
Blood (2022) 140 (Supplement 1): 3731–3733.
https://doi.org/10.1182/blood-2022-163160
Published: 2022
Journal Articles

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Steve Wagner, Alok Pachori, Georg Lenz
Journal: Blood
Blood (2022) 140 (Supplement 1): 6618–6620.
https://doi.org/10.1182/blood-2022-155995
Published: 2022